The Impact of GLP-1 Medications

Register Now

Join Us as We Discuss the What, Why and How

In 2023, the average cost per claimant for Ozempic® was $5,550, an 18% increase from 2022. Ozempic now ranks as the second highest-paid drug, behind Humira®, according to Unison Risk Advisors’ annual book of business report. The number of individuals taking Ozempic increased 135% year-over-year, contributing to the climb in overall healthcare spend*.

According to the CDC, approximately 42% of adult Americans are classified as obese, but this number exceeds 73% when adding in overweight individuals. ​​

Understanding the value of weight loss drugs, potential ROI, treatment plans and wraparound service options is critical as you determine your organization’s long-term employee benefits strategy.

Join us May 22 as our experienced panel from the Cleveland Clinic and Foundational Pharmacy Strategies discuss these important topics.

Meet the Presenters

Dr. Bruce Rogen, MD MPH FAC

Chief Medical Officer, Cleveland Clinic

Raul J. Rosenthal, MD,FASMBS

Regional Chair, Digestive Disease & Surgical Institute, Department Chair of Bariatric, Metabolic Surgery and General Surgery, Clevland Clinic

Kelly Prymicz

Co-Founder and VP of Clinical Strategy, Foundational Pharmacy Strategies

Christine Johnston

Co-Founder and Pharmacy Practice Leader, Foundational Pharmacy Strategies

Moderated by:

Tom Sigman

Strategic Solutions Leader, Unison Risk Advisors